Taking Depo-Provera More Than 2 Years and Meningioma Risk in New Jersey

When a woman calls my office worried about Depo-Provera, she has usually run into two warnings online and cannot tell where one ends and the other begins. One warning is old and is about her bones. The other is new and is about a type of brain tumor called a meningioma. They come from different research, they carry very different levels of risk, and they call for different responses. The pages selling legal services tend to blur them into a single wall of frightening bullet points, which helps no one.

So let me do something more useful. Below I separate the two issues, point you to the actual sources so you can check my work, and explain what the law in New Jersey does and does not let you do if you have been hurt. None of this is a reason to stop your shot on your own. It is a reason to have a sharper conversation with your doctor, and, if you have been diagnosed with a meningioma, to understand your timeline before a deadline quietly runs out.

What happens if you take Depo-Provera for more than 2 years?

Two long-term effects have real science behind them: a loss of bone mineral density that usually recovers after you stop, and a higher risk of meningioma that grows the longer you use the drug. Most of the other scary items you will see listed are either common short-term side effects or symptoms of a meningioma rather than direct effects of the injection.

Depo-Provera is the brand name for an injection of medroxyprogesterone acetate, a synthetic progestin given once every three months. It works by shutting down ovulation, which also lowers your estrogen, and that drop in estrogen is the thread running through the bone story.

How does long-term Depo-Provera use affect bone density?

Lower estrogen slows down bone building, so the longer you stay on the shot, the more bone mineral density you tend to lose. The guidance from the American College of Obstetricians and Gynecologists collects studies showing losses of roughly 0.5 to 3.5 percent at the hip and spine after one year, about 5.7 to 7.5 percent after two years, and around 5.2 to 5.4 percent after five years.

This is where the famous two-year figure actually comes from. Back in 2004 the FDA put a boxed warning on the label saying prolonged use may cause bone loss that increases over time and may not fully reverse, and it suggested limiting use beyond two years unless other methods do not work. That warning was about bones. It had nothing to do with brain tumors, and I think a lot of confusion online traces back to people assuming it did.

Is bone loss from Depo-Provera permanent?

For most people, no. The research shows bone density rebounds after the injections stop, although the spine recovers faster than the hip and femoral neck.

There is one wrinkle worth knowing if you started young. In an FDA-reviewed study of roughly 389 girls aged 12 to 18, those who used the shot for under two years recovered fully five years after stopping, but recovery at the hip and femoral neck was not complete in every adolescent who used it for two years or more. Teenagers are still building toward their peak bone mass, so the timing of the loss is what raises the question, not a proven lifelong deficit. ACOG's own bottom line is that bone effects should not stop a doctor from prescribing or continuing the shot, and it does not recommend routine bone scans for young users.

Why is Depo-Provera now linked to meningioma brain tumors?

A meningioma is a tumor that grows on the membranes covering the brain and spinal cord. Most are benign, but depending on size and location they can press on the brain and require surgery or years of monitoring.

The link to Depo-Provera comes out of research on progestins and these tumors. A large national study published in The BMJ in March 2024 found that prolonged use of injectable medroxyprogesterone acetate was associated with meningiomas needing surgery, and that women with tumors had used far more of the drug over time than women without them. Hormones in this family can stimulate tissue carrying hormone receptors, and meningiomas often carry those receptors, which gives the link a sensible biological basis.

How much does long-term use raise the meningioma risk?

The number you will see thrown around is roughly a fivefold increase, but the honest picture is more measured, and the real-world chance for any one woman stays low. The BMJ study put the odds ratio near 5.6 for injectable medroxyprogesterone used a year or longer, yet that estimate leaned on a very small group of users in France, where the injection is uncommon.

A larger American study published in JAMA Neurology in 2025 looked at a population where the drug is widely used and, with tighter control for other risk factors, landed on a smaller increase of about two and a half times. Even after that bump, researchers describe the absolute risk as low, which is exactly why the right reaction is an informed choice rather than panic. What both studies agree on is that the risk tracks with how long and how much of the drug you have used.

What warning did the FDA add to Depo-Provera?

In December 2025 the FDA approved a label change for Depo-Provera that warns about meningioma risk with prolonged use, separate from the older bone warning. The agency signed off on the update by letter dated December 12, 2025, and you can read the current prescribing information on the FDA label database.

That gap in time is the heart of the lawsuits. Women allege that Pfizer, the maker, knew or should have known about the meningioma risk and failed to warn American patients sooner. Pfizer maintains the product is safe when used appropriately and argues that federal rules limited what it could add to the label, a defense the court is still weighing.

What meningioma symptoms should long-term users watch for?

Many of the alarming effects you see in lists, such as seizures, vision changes, and personality shifts, are usually signs of a tumor pressing on the brain rather than direct effects of the drug. I point that out because the distinction changes what you should do about a symptom.

Warning signs that deserve a prompt medical workup include new or worsening headaches that will not let up, blurred or double vision, hearing changes, dizziness, seizures, memory trouble, and noticeable mood or personality changes. None of these proves you have a meningioma. They are reasons to get checked, especially if you used the injection for a year or more.

Should you stop taking Depo-Provera after 2 years?

That is a question for your doctor, and I want to be clear that it is not one I answer for anyone. Stopping a contraceptive on your own can lead to an unintended pregnancy, which carries its own serious risks, so the safe move is to talk through the tradeoffs before you change anything.

ACOG frames it as a balance, and I think that is the right way to see it. For most adults the benefits of reliable birth control can outweigh the bone concern, the meningioma risk for any single person stays low, and there are alternatives with no bone effect, such as an IUD or an implant, if you and your prescriber decide a switch makes sense. The point of knowing the risks is to choose well, not to quit in a hurry.

Who can file a Depo-Provera lawsuit in New Jersey?

Generally, a woman who used Depo-Provera, Depo-SubQ Provera 104, or an authorized generic for at least a year and was later diagnosed with a meningioma may have a claim. Imaging that documents the tumor is usually where I start.

In New Jersey these cases fall under the New Jersey Product Liability Act, which governs claims that a product was defective or carried inadequate warnings. The core allegation matches the federal litigation: that the warning patients received did not reflect what the manufacturer knew about the meningioma risk. Whether a particular case fits depends on the diagnosis, the length of use, and the timeline, and that is what a case review sorts out.

How long do you have to file a Depo-Provera claim in New Jersey?

New Jersey gives you two years to file, under N.J.S.A. 2A:14-2, which requires that an action for an injury to the person be commenced within two years after the cause of action accrues. For an injury like a meningioma that surfaces long after the exposure, the discovery rule matters enormously.

Under that rule, the two-year clock generally starts when you knew, or reasonably should have known, both that you were injured and that the injury may be tied to the drug, rather than on the date of your first shot. Courts apply it case by case, and other doctrines can cut a claim off entirely, so the date that controls your situation is not something I would ever ask a client to guess at. If you have a diagnosis, get the timeline reviewed sooner rather than later.

Where does the Depo-Provera litigation stand now?

The federal cases are consolidated as MDL No. 3140 in the Northern District of Florida before Judge M. Casey Rodgers, with thousands of claims on file and the number still climbing through 2026. Multidistrict litigation lets plaintiffs share evidence and pretrial work while each woman keeps her own individual case, which is different from a class action.

As of the middle of 2026 the court is working through the science, with causation hearings held in late June 2026 and the first test trial, Toney v. Pfizer, scheduled for December 7, 2026. Those early trials tend to shape how settlement talks unfold. The litigation is still accepting new cases, which is one more reason the filing deadline above is worth taking seriously.

The bottom line on long-term Depo-Provera use

If you take one thing from this page, let it be that long-term Depo-Provera use is really two separate questions, not one. The bone density loss behind the old two-year caution is real but usually recovers after you stop, and for most adults it is a tradeoff to weigh rather than a reason to quit. The meningioma risk is the newer and more serious concern, it climbs with how long and how much you use the drug, and it is why the FDA changed the United States label in December 2025 and why thousands of claims are now moving through the courts.

Knowing the difference puts you in a stronger position. It lets you make a calmer, better-informed decision with your doctor, and if you have already been diagnosed with a meningioma, it tells you why the clock matters and what your options are.

‍